AMAG Pharmaceuticals, Inc. Sustainability Profile
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 27 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, AMAG Pharmaceuticals, Inc. reported total carbon emissions of approximately 165 kg CO2e, encompassing both Scope 1 and Scope 2 emissions. This marks a slight reduction from 2021, when emissions were about 168 kg CO2e. The company has disclosed emissions data for Scope 1 and Scope 2 but has not provided specific figures for Scope 3 emissions in recent years. Historically, in 2019, AMAG reported significant emissions of approximately 1,204,000,000 kg CO2e for Scope 3, alongside 104,400,000 kg CO2e for Scope 1. The absence of Scope 2 emissions in that year indicates a focus on direct emissions and upstream activities. Despite these figures, AMAG Pharmaceuticals has not established specific reduction targets or initiatives, as indicated by the lack of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company operates under a corporate family relationship with Azurity Pharmaceuticals, Inc., which may influence its emissions data and climate strategies. Overall, while AMAG Pharmaceuticals has made some progress in reducing its emissions, the lack of comprehensive climate commitments and specific reduction targets suggests there is room for improvement in its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 2 | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000,000 | - | - |
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is AMAG Pharmaceuticals, Inc.'s Location?
AMAG Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AMAG Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
